---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-013131"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2023-10-19T23:59:59+00:00"
generated_at: "2026-06-09T21:30:10.185631+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Palatin prelim Q1: Vyleesi gross revenue $4.6M, net $2.1M, up 100% and 137% YoY

## Summary
- Gross product revenue $4.6M (+11% qoq, +100% YoY); net product revenue $2.1M (+18% qoq, +137% YoY).
- Prescriptions dispensed grew 14% over prior quarter and 88% over comparable quarter last year.
- Seventh consecutive quarter of double-digit growth in product revenue and prescriptions dispensed.
- CEO reports net revenue per prescription improving; net product revenue exceeds Vyleesi quarterly operating expenses.
- All key metrics (new patient starts, refill rates, insurance reimbursement, new prescribers) showed positive trends.

## SEC filing metadata
- accession: 0001654954-23-013131
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2023-10-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495423013131/0001654954-23-013131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495423013131/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-013131
- JSON: https://secwatch.observer/filing/0001654954-23-013131.json
- Plain text: https://secwatch.observer/filing/0001654954-23-013131.txt

## Key facts
- Earnings Releases
  PALATIN TECHNOLOGIES INC reported first quarter of fiscal year 2024 ended September 30, 2023 results: revenue $4.6 million in gross product revenue; $2.1 million in net product revenue.
  - Period: first quarter of fiscal year 2024 ended September 30, 2023
  - Revenue: $4.6 million in gross product revenue; $2.1 million in net product revenue
  - Result: preliminary results
  source text: Preliminary Quarter Ended September 30, 2023 Vyleesi ® Product Revenue Results · 7 Consecutive Quarters of Double-Digit Growth in Product Revenue and Prescriptions Dispensed · $4.6 million in Gross Product Revenue o 11% growth over prior quarter; 100% growth over comparable quarter last year · $2.1 million in Net Product Revenue o 18% growth over prior quarter;
  evidence_url: https://www.sec.gov/Archives/edgar/data/911216/000165495423013131/0001654954-23-013131-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.